Fierce Biotech11d
ALX lays off 30% of staff to pay for more trials of CD47 blocker
ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...
Bay Area biotech firm once worth more than $4B lays off 30% of staff
ALX Oncology is laying off 30% of its staff, mainly in preclinical research, to redirect money toward clinical trials, ...
Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday
Small-Cap Firms Dominate Market Rally. In this article, we are going to take a look at where ALX Oncology Holdings Inc.
Insider Monkey9d
Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday
Looking ahead, ALX Oncology Holdings Inc. (NASDAQ:ALXO) CEO Jason Lettmann said that its multiple ongoing clinical studies are set to position the company for near- and long-term success.
Why a Big Pharma player is shutting down a Bay Area site, consolidating at another
At one point, BMS said the facility would house 400 people. That was before Chairman and CEO Chris Boerner replaced Giovanni ...
Morningstar8d
Why the Global Cancer Market Could Surpass $900 Billion—And the Stocks Leading the Charge
ALX Oncology Holdings Inc. (NASDAQ: ALXO) is pushing forward with key advancements in its clinical pipeline, including the continued development of evorpacept, a CD47-blocking immunotherapy ...
Newswire8d
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
"With multiple clinical trials surpassing expectations in 2024, 2025 is shaping up to be a defining year for Oncolytics," said Wayne Pisano, Chair of Oncolytics' Board of Directors and Interim CEO.